GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Britannia Life Sciences BLAB.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.07

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2026

Revenue

C$474,834

FY2017FY2026

Net income

C$14.7m

FY2017FY2026

Free cash flow

−C$1.2m

FY2017FY2026

Shareholders' equity

C$20.7m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2019FY2018FY2017
RevenueC$474,834C$369,279C$516,831C$6.4mC$7.3mC$1.4mC$974,300C$186,000—
Operating incomeC$13.6m−C$4.5m−C$6.8mC$994,091−C$8.4mC$758,938−C$5.2m−C$5.3m−C$2.0m
Net incomeC$14.7mC$7.4m−C$4.8mC$5.1m−C$15.5m−C$157,162−C$7.1m−C$11.9m−C$2.4m
Diluted earnings per share0.090.05-0.030.03-0.10—-1.23-2.37-1.81

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2019FY2018FY2017
Total assetsC$23.9mC$11.6mC$22.3mC$23.5mC$21.1mC$21.5mC$3.2mC$5.7mC$3.2m
Cash and short-term investments——————C$254,200C$3.9mC$1.1m
Total liabilitiesC$3.1mC$5.3mC$15.6mC$12.5mC$15.6mC$18.8mC$13.2mC$9.1mC$3.9m
Debt—C$1.5mC$4.8mC$6.3mC$122,487C$2.4mC$11.1mC$5.1mC$1.8m
Shareholders' equityC$20.7mC$6.3mC$2.4mC$7.0mC$1.4m−C$202,325−C$10.1m−C$3.5m−C$697,600
Shares outstanding162m162m162m162m162m—6m5m1m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2019FY2018FY2017
Cash from operations−C$1.2m−C$2.6mC$2.1mC$2.0mC$2.8m−C$586,576−C$7.1m−C$4.0m−C$2.0m
Capital spending——−C$337,474−C$342,300−C$87,083—−C$68,400−C$711,900−C$228,200
Free cash flow−C$1.2m−C$2.6mC$1.8mC$1.7mC$2.7m−C$586,576−C$7.2m−C$4.7m−C$2.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueC$101,371−C$283,121C$377,005C$211,181C$169,769−C$5.1mC$168,264C$234,589
Operating incomeC$1.2mC$2.2mC$12.5m−C$561,448−C$682,917−C$2.6m−C$620,999−C$205,580
Net incomeC$1.2mC$3.6mC$12.1m−C$411,276−C$690,948C$9.5m−C$136,853−C$1.2m
Diluted earnings per share0.010.020.07-0.00-0.000.06-0.00-0.01
Cash from operations————−C$1.0m−C$3.0m——
Total assetsC$24.8mC$23.9mC$22.1mC$10.3mC$9.8mC$11.6mC$22.2mC$22.8m
Debt———C$2.2mC$1.5mC$1.5mC$4.4mC$4.8m
Shareholders' equityC$22.1mC$20.7mC$17.2mC$5.1mC$5.5mC$6.3mC$1.2mC$1.5m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-58.0%-19.7%—
Operating income139.2%78.1%—
Net income42.3%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin1084.3%42.8%-25.9%—
Net margin2611.5%288.0%40.9%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings0.82.0-2.70.8-0.3-67.5
Price to sales23.939.525.10.70.67.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 18 Nov 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.